deprexis is reimbursed under the US Veterans Affairs Federal Supply Schedule
Uppsala, Sweden and Hamburg, Germany, Wednesday 13. July 2022 15.30 CEST
Orexo, GAIA’s partner for the commercialization of deprexis®, GAIA’s evidence-based digital therapy for the treatment of symptoms of depression, announced today it has been granted a Veteran Affairs Federal Supply Schedule (VA FFS) contract. As of late July 2022, deprexis® will be reimbursed by the federal government and made available to federal healthcare providers, including Veterans Affairs (VA), Indian Health Service (IHS) and Department of Defense (DOD). The federal government is one of the largest payers and direct healthcare providers in the US.
Stan Sugarman, Chief Commercial Officer of GAIA AG & President of GAIA America Inc, said: “This is an incredible win for digital therapeutics in the United States. We are incredibly proud of our partner, Orexo, for securing a 10-year reimbursement pathway to make deprexis even more accessible for nearly 15 million US citizens including veterans and their families. Thank you for helping us support even more patients manage their depression.”
To read more about Orexo’s Veteran Affairs Federal Supply Schedule (VA FFS) contract for deprexis®, read the full press release here.
